The invention provides novel methods for treating 
disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. 
Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing 
cell membranes; limiting 
oxidative damage to 
cell and blood components; limiting 
cell proliferation, cell 
extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated 
chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of 
disease states, including obstructive 
respiratory disease, including 
asthma; 
colitis and Crohn's 
disease; 
central nervous system insult, including 
blood brain barrier compromise, 
ischemic stroke, and 
multiple sclerosis; 
contact dermatitis; 
psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor 
vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; 
sepsis; 
acute respiratory distress syndrome; 
tissue transplant rejection syndromes; 
autoimmune disease; 
viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of 
phosphatidylethanolamine bound to carboxymethylcellulose, 
heparin, 
hyaluronic acid, 
polyethylene glycol, and hemaccel. Disclosed herein are also new compounds comprised of 
phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.